Education
About Us
Working with TipRanks
Follow Us
Beam Therapeutics (BEAM)
NASDAQ:BEAM
BEAM Analyst Ratings
Moderate Buy
10 Buy
4 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
BEAM Stock 12 Month Forecast
Average Price Target
$46.91
▲(114.10% Upside)
| Highest Price Target$80.00 | Average Price Target$46.91 | Lowest Price Target$26.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Bernstein
Reiterated
03/24/25
Wells Fargo
Reiterated
03/21/25
Citi
Reiterated
03/13/25
William Blair
Reiterated
03/10/25
Scotiabank
Upgraded
03/10/25
H.C. Wainwright
Reiterated
03/10/25
Leerink Partners
Reiterated
03/10/25
BMO Capital
Reiterated
03/10/25
Bank of America Securities
Reiterated
03/10/25
JonesTrading
Upgraded
03/10/25
Barclays
$31
Hold
41.49%
Upside
Reiterated
02/26/25
Analysts' Opinions Are Mixed on These Healthcare Stocks: Addus Homecare (NASDAQ: ADUS) and Beam Therapeutics (NASDAQ: BEAM)
Jefferies
$23→$30
Hold
36.92%
Upside
Reiterated
02/25/25
Beam Therapeutics Inc (BEAM) PT Raised to $30 at JefferiesJefferies analyst Michael Yee raised the price target on Beam Therapeutics Inc (NASDAQ: BEAM) to $30.00 (from $23.00) while maintaining a Hold rating.
RBC Capital
$26
Hold
18.67%
Upside
Reiterated
02/25/25
RBC Capital Reaffirms Their Hold Rating on Beam Therapeutics (BEAM)
Cantor Fitzgerald
―
Buy
―
Upgraded
01/29/25
Beam Therapeutics upgraded to Overweight from Neutral at Cantor FitzgeraldBeam Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
Wedbush
$57
Buy
160.16%
Upside
Reiterated
12/09/24
Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (NASDAQ: BEAM) and Ovid Therapeutics (NASDAQ: OVID)
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Bernstein
Reiterated
03/24/25
Wells Fargo
Reiterated
03/21/25
Citi
Reiterated
03/13/25
William Blair
Reiterated
03/10/25
Scotiabank
Upgraded
03/10/25
H.C. Wainwright
Reiterated
03/10/25
Leerink Partners
Reiterated
03/10/25
BMO Capital
Reiterated
03/10/25
Bank of America Securities
Reiterated
03/10/25
JonesTrading
Upgraded
03/10/25
Barclays
$31
Hold
41.49%
Upside
Reiterated
02/26/25
Analysts' Opinions Are Mixed on These Healthcare Stocks: Addus Homecare (NASDAQ: ADUS) and Beam Therapeutics (NASDAQ: BEAM)
Jefferies
$23→$30
Hold
36.92%
Upside
Reiterated
02/25/25
Beam Therapeutics Inc (BEAM) PT Raised to $30 at JefferiesJefferies analyst Michael Yee raised the price target on Beam Therapeutics Inc (NASDAQ: BEAM) to $30.00 (from $23.00) while maintaining a Hold rating.
RBC Capital
$26
Hold
18.67%
Upside
Reiterated
02/25/25
RBC Capital Reaffirms Their Hold Rating on Beam Therapeutics (BEAM)
Cantor Fitzgerald
―
Buy
―
Upgraded
01/29/25
Beam Therapeutics upgraded to Overweight from Neutral at Cantor FitzgeraldBeam Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
Wedbush
$57
Buy
160.16%
Upside
Reiterated
12/09/24
Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (NASDAQ: BEAM) and Ovid Therapeutics (NASDAQ: OVID)
BEAM Analyst Recommendation Trends
Rating
Nov 24
Dec 24
Jan 25
Feb 25
Mar 25
Strong Buy
6
12
14
13
13
Buy
3
4
8
8
11
Hold
8
8
9
9
9
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
17
24
31
30
33
Each month's total comprises the sum of three months' worth of ratings.
BEAM Financial Forecast
BEAM Stock Forecast FAQ
What is BEAM’s average 12-month price target, according to analysts?
Based on analyst ratings, Beam Therapeutics’s 12-month average price target is $46.91.
What is BEAM’s upside potential, based on the analysts’ average price target?
Beam Therapeutics has 114.10% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is BEAM a Buy, Sell or Hold?
Beam Therapeutics has a consensus rating of Moderate Buy which is based on 10 buy ratings, 4 hold ratings and 0 sell ratings.
What is Beam Therapeutics’s price target?
The average price target for Beam Therapeutics is $46.91. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $80.00 ,the lowest forecast is $26.00. The average price target represents 114.10% Increase from the current price of $21.91.
The highest analyst price target is $80.00 ,the lowest forecast is $26.00. The average price target represents 114.10% Increase from the current price of $21.91.
What do analysts say about Beam Therapeutics?
Beam Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 14 Wall Streets Analysts.
How can I buy shares of BEAM?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.